Bernie Sanders goes after BioMarin's shot at a record drug price, threatening to break the patent
Last week at JP Morgan, BioMarin CEO JJ Bienaimé laid out his thoughts on pricing the leading gene therapy for hemophilia A at $2 million to $3 million a shot. Payers would support that, he said, putting the biotech on track to launching a treatment that could top the price of Novartis’s $2.1 million gene therapy for spinal muscular atrophy.
And with that, he earned some high-level attention from a would-be president of the United States.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.